(Q35829431)

10 August 2017

1 reference

title

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice (English)

1 reference

10 August 2017

phase I clinical trial

0 references

cytotoxicity

0 references

author name string

Wendy R Parulekar

series ordinal

1

1 reference

PubMed ID

15240782

10 August 2017

Elizabeth A Eisenhauer

series ordinal

2

1 reference

PubMed ID

15240782

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Journal of the National Cancer Institute

10 August 2017

1 reference

10 August 2017

96

1 reference

10 August 2017

990-997

1 reference

10 August 2017

13

1 reference

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

10 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Development of target-based antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Novel endpoints and design of early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH182

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH182

1 reference

10 August 2017

1 reference

PubMed ID

15240782